Experts explore the evolving standards of care for EGFR-mutated advanced NSCLC, highlighting therapy selection and innovative combination strategies.
Back
Traversing Frontline Treatment Options in EGFR-Mutated Non–Small Cell Lung Cancer
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, detail management strategies in EGFR-mutated NSCLC.
Traversing Frontline Treatment Options in EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
The FDA approval of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.
The FDA-approved combination of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.
Explore the impact of CNS metastasis on prognosis in EGFR mutant lung cancer and the promising results from the MARIPOSA trial.
Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.
Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.
Experts discuss the potential of amivantamab and velertinib in early-stage lung cancer treatment, emphasizing the need for careful patient management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
The OncFive: Top Oncology Articles for the Week of 8/2
5